Familial hypercholesterolemia in the Czech Republic in 2016

Česká verzia

Authors: Tomáš Freiberger ¹; Martina Vaclová ²; Lukáš Tichý ³; Vladimír Soška ^4,5,6; Vladimír Bláha ⁷; Lenka Fajkusová ³; Richard Češka ²; Michal Vrablík ²
Authors place of work: Genetická laboratoř Centra kardiovaskulární a transplantační chirurgie, Brno ¹; III. interní klinika 1. LF UK a VFN v Praze ²; Centrum molekulární biologie a genové terapie FN Brno ³; Oddělení klinické biochemie a ICRC – oddělení kardiovaskulárních chorob, FN u sv. Anny v Brně ⁴; Katedra laboratorních metod, LF MU Brno ⁵; II. interní klinika LF MU a FN U sv. Anny v Brně ⁶; III. interní gerontometabolická klinika LF UK a FN Hradec Králové ⁷
Published in the journal: Vnitř Lék 2016; 62(11): 924-928
Category: Reviews

Summary

Familial hypercholesterolemia (FH) is the most frequent autosomal dominant hereditary disease which is characterized by a decreased LDL-cholesterol catabolism and early clinical manifestation of atherosclerosis affecting blood vessels. The MedPed (Make early diagnosis to Prevent early deaths) project aims to diagnose patients with FH as early as possible, so that they can profit the most from a therapy started in a timely manner and avoid premature cardiovascular events. Currently, as of 31 October 2016, the Czech national database keeps records of 6 947 patients with FH from 5 223 families. Considering the prevalence of FH equalling 1 : 250, this represents 17.4 % of the overall expected number of patients with FH in the Czech Republic. Determining the mutation responsible for FH, now using a next generation sequencing technology in the Czech Republic, brings with it higher diagnostic accuracy, better cooperation of patients and in particular facilitation of cascade screening in families. Although we are among the most successful countries in the world with regard to FH detection, the majority of patients are still undiagnosed. Moreover, as it turns out, most FH patients do not reach the target values with the current therapeutic possibilities. In this regard the newly approved hypolipidemic drugs, PCSK9 inhibitors, to be hopefully available also in the Czech Republic in the near future for chosen patients with FH at high risk, hold great promise.

Key words:
cascade screening – familial hypercholesterolemia – LDL-cholesterol – MedPed

Zdroje

1. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015; 243(1): 257–259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021 >.

2. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutarylcoenzyme A reduktase activity associated with over production of cholesterol. Proc Natl Acad Sci USA 1973; 70(10): 2804–2808.

3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL (eds) et al. The metabolic and molecular bases of inherited disease. 8th ed. McGraw-Hill: New York 2001. 2. Vol: 2863–2914. ISBN 978–0071363211.

4. Benn M, Watts GF, Tybjaerg-Hansen A et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97(11): 3956–364. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–1563>. Erratum in J Clin Endocrinol Metab 2014; 99: 4758–4759.

5. Sjouke B, Kusters DM, Kindt I et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36(9): 560–565. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu058>

6. Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675–700.

7. Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37: 402–407.

8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232(4746): 34–47.

9. Huijgen R, Kindt I, Defesche JC et al. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individual stested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J 2012; 33(18): 2325–2330. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs038>.

10. Cuchel M, Bruckert E, Ginsberg HN et al. [European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia]. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146–2157. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu274>.

11. Baigent C, Blackwell L, Emberson J, Holland LE et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681.

12. Raal FJ, Stein EA, Dufour R et al. [RUTHERFORD-2 Investigators]. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385(9965): 331–340. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61399–4>.

13. Kastelein JJ, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36(43): 2996–3003. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv370>.

14. Nordestgaard BG, Chapman MJ, Humphries SE et al. [European Atherosclerosis Society Consensus Panel]. Familial hypercholesterolaemia is under diagnosed and under treated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478–3490a. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht273>.

15. Pijlman AH, Huijgen R, Verhagen SN et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010; 209(1): 189–194. Dostupné z DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.014>.

16. Perez de Isla L, Alonso R, Watts GF et al. [SAFEHEART Investigators]. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up. J Am Coll Cardiol 2016; 67(11): 1278–1285. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.01.008>.

17. van Aalst-Cohen ES, Jansen AC, Tanck MW et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 2006; 27(18): 2240–2246.

18. Watts GF, Gidding S, Wierzbicki AS et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171(3): 309–325. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2013.11.025>.

19. Santos RD, Gidding SS, Hegele RA et al. [International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel]. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4(9): 850–861. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(16)30041–9>.

20. Khera AV, Won HH, Peloso GM et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 2016; 67(22): 2578–2589. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.03.520>.

21. Talmud PJ, Shah S, Whittall R et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381(9874): 1293–1301. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)62127–8>

22. Futema M, Plagnol V, Li K et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014; 51(8): 537–544. Dostupné z DOI: <http://dx.doi.org/10.1136/jmedgenet-2014–102405>.

23. Norsworthy PJ, Vandrovcova J, Thomas ER et al. Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet 2014; 15: 70. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2350–15–70>.

24. Freiberger T, Vrablík M. 15 let projektu MedPed v České republice. Hypertenze a kardiovaskulární prevence 2013; 2(5): 58–60.

25. Watts GF, Ding PY, George P et al. Translational Research for Improving the Care of Familial Hypercholesterolemia: The “Ten Countries Study” and Beyond. J Atheroscler Thromb 2016; 23(8): 891–900. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.35949>.

26. O‘Brien EC, Roe MT, Fraulo ES et al. Rationale and design of the familial hypercholesterolemia foundation Cascade Screening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J 2014; 167(3): 342–349. e17. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2013.12.008>.

27. Ceska R et al. ScreenPro FH – Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design. Submitted. Dostupné z WWW: <http://screenprofh.com/>.